Accordingly, the European Society of Cardiology guidelines from 2023 recommend sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and GLP-1 Ras as a preferred glucose-lowering therapy for patients with T2DM and ASCVD [50]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.